CIMZIA

LOE ApproachingmAb

certolizumab pegol

BLAINJECTIONINJECTABLE
Approved
Apr 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Tumor Necrosis Factor Receptor Blocking Activity

Pharmacologic Class:

Tumor Necrosis Factor Blocker

Clinical Trials (5)

NCT04643483Phase 3Withdrawn

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

Started Jun 2021
0
Crohn's Disease
NCT04740814Phase 1Completed

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Started Feb 2021
33 enrolled
Rheumatoid Arthritis
NCT04163016Phase 1Completed

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Started Jun 2020
22 enrolled
Rheumatoid ArthritisPsoriatic ArthritisCrohn's Disease+2 more
NCT04123795Phase 3Active Not Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

Started Jan 2020
49 enrolled
Moderate Chronic Plaque PsoriasisSevere Chronic Plaque PsoriasisMixed Guttate/Plaque Psoriasis
NCT04053881N/ACompleted

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

Started Aug 2019
412 enrolled
Plaque Psoriasis